{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:26:40Z","timestamp":1787372800292,"version":"build-2736575974"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7727-26","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:10:59Z","timestamp":1787091059000},"source":"Crossref","is-referenced-by-count":0,"title":["First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review"],"prefix":"10.2169","author":[{"given":"Yoshio","family":"Nakano","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroka","family":"Serizawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kuze","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwao","family":"Gohma","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Yasuhara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sakai City Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377: 829-838, 2017.","DOI":"10.1056\/NEJMoa1704795"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shaw AT, Bauer TM, De Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383: 2018-2029, 2020.","DOI":"10.1056\/NEJMoa2027187"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 42: 3400-3409, 2024.","DOI":"10.1200\/JCO.24.00581"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yeung AML, Chow JCH. Management of pulmonary large-cell neuroendocrine carcinoma (LCNEC): an updated review. Clin Lung Cancer 27: 85-97, 2026.","DOI":"10.1016\/j.cllc.2026.01.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chen D, Ma S, Sun L, et al. EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report. Ann Transl Med 11: 134, 2023.","DOI":"10.21037\/atm-22-6062"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hayashi N, Fujita A, Saikai T, et al. Large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement with response to alectinib. Intern Med 57: 713-716, 2018.","DOI":"10.2169\/internalmedicine.9368-17"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tashiro T, Imamura K, Tomita Y, et al. Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK rearrangement-positive large cell neuroendocrine carcinoma. Int J Mol Sci 21: 9705, 2020.","DOI":"10.3390\/ijms21249705"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kemik F, Bulutay P, K\u0131k\u0131l\u0131 C\u0130, et al. First-line lorlatinib treatment in a 19-year-old patient with ALK-rearranged pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. Anticancer Drugs 37: 82-88, 2026.","DOI":"10.1097\/CAD.0000000000001754"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Omachi N, Shimizu S, Kawaguchi T, et al. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. J Thorac Oncol 9: e40-e42, 2014.","DOI":"10.1097\/JTO.0000000000000103"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zheng Q, Zheng M, Jin Y, et al. ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature. Onco Targets Ther 11: 4991-4998, 2018.","DOI":"10.2147\/OTT.S172124"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang Y, Tian P, Wang W, et al. A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174 L mutation after resistance. Precis Clin Med 2: 1-5, 2019.","DOI":"10.1093\/pcmedi\/pbz005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Leblanc A, Owen S, Fiset PO, et al. Metastatic large-cell neuroendocrine lung carcinoma with ALK fusion oncogene with partial response to alectinib. JCO Precis Oncol 5: 802-807, 2021.","DOI":"10.1200\/PO.20.00348"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Masuda K, Saiki M, Shimamura S, et al. Dramatic response to alectinib in an ALK-positive LCNEC patient with a poor performance status: a case report. Respirol Case Rep 9: e0817, 2021.","DOI":"10.1002\/rcr2.817"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fu Z, Zhu G, Wang L, et al. Case report: a pregnant woman diagnosed as ALK-rearrangement lung large cell neuroendocrine cancer with brain metastasis. Front Oncol 12: 823813, 2022.","DOI":"10.3389\/fonc.2022.823813"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Akhoundova D, Haberecker M, Fritsch R, et al. Targeting ALK in neuroendocrine tumors of the lung. Front Oncol 12: 911294, 2022.","DOI":"10.3389\/fonc.2022.911294"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wiedemann C, Kazdal D, Cvetkovic J, et al. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. Cold Spring Harb Mol Case Stud 8: a006234, 2022.","DOI":"10.1101\/mcs.a006234"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kobayashi T, Uehara Y, Watanabe K, et al. Successful treatment of ALK-positive large-cell neuroendocrine carcinoma of the lung with sequential ALK inhibitors: a case report. JTO Clin Res Rep 4: 100538, 2023.","DOI":"10.1016\/j.jtocrr.2023.100538"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mu X, Li Y. Case report: therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective. Front Pharmacol 15: 1413897, 2024.","DOI":"10.3389\/fphar.2024.1413897"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 19: e43-e55, 2018.","DOI":"10.1016\/S1470-2045(17)30689-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. George J, Walter V, Peifer M, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 9: 1048, 2018.","DOI":"10.1038\/s41467-018-03099-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22: 3618-3629, 2016.","DOI":"10.1158\/1078-0432.CCR-15-2946"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7727-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:10:53Z","timestamp":1787371853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7727-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7727-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7727-26"}}